Key points from article :
British biotech company OutSee has raised £1.8 million in seed funding to advance its predictive genomics platform and therapeutic programs. Based in Cambridge, OutSee is focusing on complex conditions such as central nervous system and metabolic disorders, where traditional approaches often fall short. At the core of its strategy is Nomaly, a proprietary AI-driven tool that interprets disease risk and phenotype directly from a person’s genome, without relying on pre-existing genetic associations.
Unlike conventional methods that search for known correlations, Nomaly uses a “hypothesis-free” approach to reveal the biological mechanisms underpinning disease. This allows OutSee to identify novel drug targets that are often missed by tools requiring large patient cohorts or established genetic links. According to Dr Julian Gough, OutSee’s founder and CEO, the platform has already shown promising early results in diseases like Alzheimer’s and Parkinson’s. The company is also involved in projects funded by Innovate UK, with a focus on dementia and age-related conditions.
Nomaly’s strength lies in its ability to derive meaningful insights even from small datasets, enabling better patient stratification and progress toward precision medicine. It can detect complex genetic interactions that might be invisible to traditional association-based techniques, offering an advantage for early-stage drug discovery and target validation.
The funding round, led by Ahren Innovation Capital with support from Kadmos Capital, Empirical Ventures, and Panacea Ventures, will support OutSee’s continued development of Nomaly, expansion of internal drug discovery efforts, and partnerships with pharmaceutical and biotech companies. As Ahren’s Dr Joanna Green put it, OutSee’s approach enables researchers to explore genomic data with an unprecedented level of precision, unlocking new possibilities for therapeutic innovation across a wide range of diseases.
